PENSACOLA, FL, February 20, 2024 – ActiGraph and Cambridge Cognition, leading providers of wearable digital health technologies and CNS assessments, respectively, announced a new strategic partnership to deliver a broad suite of assessments to provide a fully-rounded view of mental and physical capabilities. The companies’ technologies have been used together by top 20 pharma companies in clinical trials already.
Cambridge Cognition has joined ActiGraph’s AccelerantTM partnership program, designed to advance the use of digital health technologies (DHTs) in clinical development by simplifying CROs’ and technology vendors’ access to raw data streams. As part of this strategic partnership, Cambridge Cognition and ActiGraph will combine their collective expertise in digital data collection to enhance assessment capabilities in CNS trials in areas where there is a large unmet need, such as schizophrenia and dementia.
Cambridge Cognition’s technology can be used at home or in-clinic, giving sponsor organizations and research institutions flexibility to reliably capture important clinical measures. Based on over 30 years of scientific validation and innovation, Cambridge Cognition’s platform offers accurate and sensitive digital cognitive assessments to academic research, drug development, and healthcare professionals.
"Digital health technologies give us the ability to collect data objectively during a patient’s everyday life,” says Christine Guo, Chief Scientific Officer, ActiGraph. “This is especially important in CNS disorders where conventional assessments are prone to subjective biases. We are excited about this partnership with Cambridge Cognition to provide advanced clinical insights to study teams conducting CNS trials.”
“CNS disorders are characterised by a host of heterogeneous symptoms which impact daily life, but that are often inadequately addressed by existing treatments. Our partnership with ActiGraph represents an exciting bringing together of expertise in objective digital measures of actigraphy, speech, and cognition that will help accelerate the development of treatments for patients and improve efficiency in clinical trials,” says Francesca Cormack, Chief Scientist, Cambridge Cognition.
***
About ActiGraph
ActiGraph is pioneering the digital transformation of clinical research. We provide end-to-end digital health technology (DHT) solutions by integrating and operationalizing the best hardware, software, and algorithms to generate reliable evidence and get the right treatments to the right patients, faster. ActiGraph’s medical-grade wearable technology platform has been used to capture real-world, continuous digital measures of activity, sleep, and mobility for nearly 250 industry-sponsored clinical trials and thousands of academic research studies. Appearing in over 24,000 published scientific papers to date, ActiGraph is the most experienced and trusted wearable technology partner in the industry.
About Cambridge Cognition
Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health, speech and language and other specialist measurements in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.
